The recombinant human monoclonal antibody nasal spray against SARS-CoV-2 (F61 Nasal Spray) of Sinopharm's Wuhan Institute of Biological Products has received approval for clinical trials from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results